Journal September 16, 2026 6 min read

Semaglutide: sourcing, documentation and price

A research-supply overview of semaglutide: identifiers, analytical documentation, and the trial landscape that shapes sourcing and price.

peptides-pro Editorial

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist supplied for laboratory research. It is also known by the research codes and trade names used across the literature, and it belongs to the incretin mimetic class. The evidence block for this page does not provide a sequence, molecular formula, or molecular weight, so none are stated here; the analytical review cited below covers methods for determining semaglutide in pharmaceutical formulations and biological matrices [9].

The work described on this page centres on the GLP-1 receptor and its downstream incretin signalling.

Research Studies

Semaglutide and metabolic syndrome after gestational diabetes

A randomized effectiveness-implementation Hybrid Type 1 trial is evaluating immediate postpartum semaglutide following a pregnancy complicated by gestational diabetes mellitus (GDM). A total of 226 postpartum individuals with recent GDM are randomized 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase. The primary effectiveness outcome, development of metabolic syndrome, is assessed at 6 months postpartum. Participants then enter a 6-month maintenance phase in which continuation, discontinuation, or initiation of semaglutide reflects patient and clinician decisions [1].

Semaglutide and cardiometabolic profile in schizophrenia with metabolic syndrome

Patients with schizophrenia on second-generation antipsychotics carry a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options. A multicentre, double-blind, placebo-controlled randomized trial is testing whether adjunctive oral semaglutide 3 mg once daily, added to treatment as usual, reduces 10-year cardiovascular risk (QRISK3) and improves insulin resistance, lipids, weight and metabolic biomarkers over 24 weeks compared with placebo, while confirming psychiatric safety and tolerability [2].

Semaglutide and muscle preservation in older adults starting therapy

A randomized, double-blind, placebo-controlled trial is evaluating whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care. Participants receive calcium-HMB plus vitamin D3 or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6; secondary assessments include body composition, muscle strength, physical performance, gait, physical activity, and resting metabolic rate [3].

Semaglutide and switching to zovaglutide in adults with obesity

The HORIZON-SWITCH-SZ study evaluates the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity [4].

Semaglutide dose effects on craving and alcohol use outcomes

A study is examining two doses of semaglutide, 1.0 mg and 2.0 mg, versus placebo in patients with alcohol use disorder (AUD) and obesity, to assess whether these doses improve alcohol craving, stress, and alcohol use outcomes [5].

Semaglutide and zenagamtide in excess body weight

A research study is investigating how well zenagamtide helps people with excess body weight lose weight compared with semaglutide [6].

Semaglutide and early reinitiation after sleeve gastrectomy in youth

A Phase 3a, randomized, parallel-controlled trial compares early reinitiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial involves 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants are randomized to semaglutide 2.4 mg weekly or standard care for 24 months, with outcomes assessed at 1 month, the day of surgery, and 1, 3, 6, 9, 12, 18, and 24 months postoperatively. The hypothesis is that early reinitiation will be safe [7].

Semaglutide and cardiovascular health in breast cancer survivors on aromatase inhibitors

A phase IV trial studies whether adding semaglutide to structured lifestyle support improves heart and blood vessel health in postmenopausal obese breast cancer survivors taking an aromatase inhibitor. In this population, obesity raises the risk of heart and blood vessel problems. The structured lifestyle support includes counselling on nutrition and physical activity with specific recommendations for individuals to follow [8].

Semaglutide and analytical determination in formulations and biological matrices

A comprehensive review reports that semaglutide is a potent long-acting GLP-1 receptor agonist with therapeutic efficacy for type 2 diabetes and obesity, and that widespread clinical use has driven increasing demand for analytical techniques to identify semaglutide in pharmaceutical formulations and biological matrices [9].

Semaglutide and treatment patterns among adult users

A community pharmacy-based cross-sectional survey investigated semaglutide treatment patterns among Danish adult users for weight management, noting that users may not follow the recommended treatment regimen. The questionnaire-based survey was conducted across 28 Danish community pharmacies between March and May 2025 [10].

Semaglutide and neuropsychiatric outcomes

Neuropsychiatric safety concerns, including depression and suicidal ideation, have emerged during the expanding clinical use of incretin-based therapies for type 2 diabetes mellitus and obesity. Whether risks differ across successive generations of incretin-based therapies remains uncertain [11].

Semaglutide and gallbladder-related adverse events

A pooled analysis of placebo-controlled STEP trials examined gallbladder-related adverse events with semaglutide 2.4 mg [12].

Comparison of study designs

Study	Population	Design	Primary outcome
NCT07797036 [1]	Postpartum individuals with recent GDM	Randomized, Hybrid Type 1	Metabolic syndrome at 6 months
NCT07770282 [2]	Schizophrenia with metabolic syndrome	Multicentre, double-blind, placebo-controlled	10-year cardiovascular risk (QRISK3)
NCT07760948 [3]	Adults 65–85 with type 2 diabetes	Randomized, double-blind, placebo-controlled	Appendicular lean mass at month 6
NCT07812597 [4]	Adults with obesity	Switch study	Safety and tolerability
NCT07772960 [5]	AUD and obesity	Dose-comparison vs placebo	Alcohol craving, stress, alcohol use
NCT07668414 [6]	Excess body weight	Comparative	Weight loss
NCT06934655 [7]	Youth with severe obesity post-sleeve gastrectomy	Phase 3a, randomized, parallel-controlled	Safety
NCT07769047 [8]	Postmenopausal obese breast cancer survivors on aromatase inhibitors	Phase IV	Heart and blood vessel health

Sourcing and documentation

For laboratory research, semaglutide is supplied as a lyophilized powder or in solution, and the analytical review cited above describes methods for its determination in pharmaceutical formulations and biological matrices [9]. Documentation accompanying research-grade material typically includes a certificate of analysis, a batch number, and a purity figure determined by an appropriate analytical method. The evidence block does not provide a price, a catalogue number, or a purity specification for any specific product, so no such values are stated here.

Price

The evidence block contains no pricing information for semaglutide. Price for research-grade material is set by the supplier and depends on quantity, purity, and documentation; no figure can be given from the sources available for this page.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.